Abstract | AIM: To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients. MATERIALS AND METHODS: Two hundred and fifty-four type 2 diabetic patients were randomized to take orlistat 120 mg three times a day or placebo for 12 months. We evaluated at baseline and after 3, 6, 9 and 12 months: leptin, tumor necrosis factor ( TNF)-alpha, adiponectin (ADN), vaspin and high-sensitivity C-reactive protein ( HS-CRP), body weight, waist circumference, body mass index (BMI), lipid profile, glycemic profile, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance index (HOMA-IR). RESULTS: Regarding inflammatory parameters, there was a significant improvement of ADN and TNF-alpha, and a faster decrease of leptin and HS-CRP in the orlistat group compared with the control group. We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. A faster improvement of glycemic profile and FPI was obtained with orlistat compared with the controls. Also, there was a significant reduction of lipid profile with orlistat, not reached with placebo. CONCLUSIONS:
Orlistat was more effective than placebo in ameliorating inflammatory parameters such as ADN and TNF-alpha, and anthropometric parameters.
|
Authors | Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Angela D'Angelo, Elena Fogari, Ilaria Palumbo, Sabrina Randazzo, Arrigo F G Cicero |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 12
Pg. 1971-82
(08 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20569086
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- ADIPOQ protein, human
- Adiponectin
- Anti-Obesity Agents
- Biomarkers
- Blood Glucose
- Hypoglycemic Agents
- Inflammation Mediators
- Insulin
- Lactones
- Leptin
- Lipids
- SERPINA12 protein, human
- Serpins
- Tumor Necrosis Factor-alpha
- C-Reactive Protein
- Orlistat
|
Topics |
- Adiponectin
(blood)
- Anti-Obesity Agents
(adverse effects, therapeutic use)
- Biomarkers
(blood)
- Blood Glucose
(metabolism)
- Body Mass Index
- Body Weight
- C-Reactive Protein
(metabolism)
- Diabetes Mellitus, Type 2
(drug therapy, immunology, metabolism, physiopathology)
- Double-Blind Method
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Inflammation Mediators
(blood)
- Insulin
(blood)
- Insulin Resistance
- Italy
- Lactones
(adverse effects, therapeutic use)
- Leptin
(blood)
- Lipids
(blood)
- Male
- Middle Aged
- Obesity
(drug therapy, immunology, metabolism, physiopathology)
- Orlistat
- Placebo Effect
- Serpins
(blood)
- Time Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(blood)
- Waist Circumference
|